Related references
Note: Only part of the references are listed.Obestatin Increases the Regenerative Capacity of Human Myoblasts Transplanted Intramuscularly in an lmmunodeficient Mouse Model
Icia Santos-Zas et al.
MOLECULAR THERAPY (2017)
Obestatin controls the ubiquitin-proteasome and autophagy-lysosome systems in glucocorticoid-induced muscle cell atrophy
Tania Cid-Diaz et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2017)
Recent developments in Duchenne muscular dystrophy: facts and numbers
Maggie C. Walter et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2017)
Obestatin controls skeletal muscle fiber-type determination
Icia Santos-Zas et al.
SCIENTIFIC REPORTS (2017)
Delivery is key: lessons learnt from developing splice-switching antisense therapies
Caroline Godfrey et al.
EMBO MOLECULAR MEDICINE (2017)
β-Arrestin scaffolds and signaling elements essential for the obestatin/GPR39 system that determine the myogenic program in human myoblast cells
Icia Santos-Zas et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles
Cecile Peccate et al.
HUMAN MOLECULAR GENETICS (2016)
S6K1 Is Required for Increasing Skeletal Muscle Force during Hypertrophy
Manuela Marabita et al.
CELL REPORTS (2016)
Skeletal muscle characteristics are preserved in hTERT/cdk4 human myogenic cell lines
Matthew Thorley et al.
SKELETAL MUSCLE (2016)
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy
Joe W. McGreevy et al.
DISEASE MODELS & MECHANISMS (2015)
Action of Obestatin in Skeletal Muscle Repair: Stem Cell Expansion, Muscle Growth, and Microenvironment Remodeling
Uxia Gurriaran-Rodriguez et al.
MOLECULAR THERAPY (2015)
Studying the role of dystrophin-associated proteins in influencing Becker muscular dystrophy disease severity
J. C. van den Bergen et al.
NEUROMUSCULAR DISORDERS (2015)
Intercellular: local and systemic actions of skeletal muscle PGC-1s
Jorge C. Correia et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2015)
Wnt7a stimulates myogenic stem cell motility and engraftment resulting in improved muscle strength
C. Florian Bentzinger et al.
JOURNAL OF CELL BIOLOGY (2014)
Rescue of dystrophic skeletal muscle by PGC-1α involves restored expression of dystrophin-associated protein complex components and satellite cell signaling
Katrin Hollinger et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2013)
The mdx mouse model as a surrogate for Duchenne muscular dystrophy
Terence A. Partridge
FEBS JOURNAL (2013)
Muscle type and fiber type specificity in muscle wasting
Stefano Ciciliot et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2013)
AAV Genome Loss From Dystrophic Mouse Muscles During AAV-U7 snRNA-mediated Exon-skipping Therapy
Maeva Le Hir et al.
MOLECULAR THERAPY (2013)
Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches
Rebecca J. Fairclough et al.
NATURE REVIEWS GENETICS (2013)
The Obestatin/GPR39 System Is Up-regulated by Muscle Injury and Functions as an Autocrine Regenerative System
Uxia Gurriaran-Rodriguez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Rescue of Dystrophic Skeletal Muscle by PGC-1α Involves a Fast to Slow Fiber Type Shift in the mdx Mouse
Joshua T. Selsby et al.
PLOS ONE (2012)
Current Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMD
Christophe Pichavant et al.
MOLECULAR THERAPY (2011)
Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders
Kamel Mamchaoui et al.
SKELETAL MUSCLE (2011)
Signaling pathways perturbing muscle mass
David J. Glass
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2010)
Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin
Dejia Li et al.
JOURNAL OF CELL SCIENCE (2010)
Immortalized Skin Fibroblasts Expressing Conditional MyoD as a Renewable and Reliable Source of Converted Human Muscle Cells to Assess Therapeutic Strategies for Muscular Dystrophies: Validation of an Exon-Skipping Approach to Restore Dystrophin in Duchenne Muscular Dystrophy Cells
Soraya Chaouch et al.
HUMAN GENE THERAPY (2009)
IRES-Mediated Translation of Utrophin A Is Enhanced by Glucocorticoid Treatment in Skeletal Muscle Cells
Pedro Miura et al.
PLOS ONE (2008)
MEF2: a central regulator of diverse developmental programs
Matthew J. Potthoff et al.
DEVELOPMENT (2007)
Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers
Matthew J. Potthoff et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
PGC-1α regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy
Christoph Handschin et al.
GENES & DEVELOPMENT (2007)
Severe muscular dystrophy in mice that lack dystrophin and α7 integrin
Jachinta E. Rooney et al.
JOURNAL OF CELL SCIENCE (2006)
Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?
P Miura et al.
TRENDS IN MOLECULAR MEDICINE (2006)
Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1α, drives utrophin gene expression at the neuromuscular junction
LM Angus et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2005)
Signaling chromatin to make muscle
TA McKinsey et al.
CURRENT OPINION IN CELL BIOLOGY (2002)
Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres
J Lin et al.
NATURE (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Dystrophin and muscular dystrophy: Past, present, and future
KF O'Brien et al.
MOLECULAR GENETICS AND METABOLISM (2001)
Enhanced expression of the α7β1 integrin reduces muscular dystrophy and restores viability in dystrophic mice
DJ Burkin et al.
JOURNAL OF CELL BIOLOGY (2001)
Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation
TA McKinsey et al.
NATURE (2000)
Share Paper
